Studies have demonstrated that administering adjuvant systemic therapy to patients with residual disease post-NST, particularly in triple-negative breast cancer (TNBC) or human epidermal growth factor receptor 2 (HER2)-positive breast cancer, significantly enhances OS [18,19]. The gene discussed is ERBB2; the disease is breast carcinoma.